2 collega's in 1 auto

Laat ze daar eens op gaan handhaven

Collega's die de hele dag samen optrekken.... rot toch op met de 1,5 meter spelletje.

gegevens waren er al vroeg

. rot toch op met de 1,5 meter spelletje.

omdat we met 3 collega's de gehele dag samen aan het werk zijn, waarom mogen we dan niet samen in een auto zitten, zonder het risico van een boute.

En met een ziekenhuis opname van 11.552 mensen met Corona zullen de ziekenhuizen wel overvol liggen.

Driedubbel

Ach ja wéér onze vitale Rikus

Maarja, als je te vroeg je vertrekprocedure start en daardoor overstappende mensen niet mee kunnen.

Nee, de vertekprocedure start je alvast zodat de deurtjes dicht zitten voor de aangegeven vertrektijd. Zo zorg je dat de trein precies op tijd vertrekt.

Ik had er slechts 7 van de 12 goed. Hakken over de sloot...

Hij die het snappe snappe het maar ik snap er niks van

Twee vrienden lopen door het park. Ze komen toevallig een derde vriend tegen en gaan even samen op een bankje zitten om bij te kletsen. Zijn ze dan ook in overtreding?

-----

Nee. Omdat het geen georganiseerde bijeenkomst betreft (waar geen afspraak aan vooraf is gegaan), is hier geen sprake van een samenkomst. Het is aan de handhaver om dat in te schatten. Hierin vertrouwen veiligheidsregio’s op het fingerspitzengefühl van de boa of politieagent.

Mag ik meer dan drie vrienden thuis uitnodigen?

------

Het kabinet heeft een oproep gedaan om maximaal drie mensen thuis te ontvangen en anderhalve meter afstand te houden. Maar dat is geen verbod. Je bent dus niet in overtreding als je meer mensen ontvangt.

Hierin vertrouwen veiligheidsregio’s op het fingerspitzengefühl van de boa

Vreemd, hier zijn invallen voor gedaan en hebben mensen boetes gekregen. Schijt aan Corona party's mogen dus gewoon.

Hashtag alleen samen krijgen we Corona er onder en zo

Vreemd, hier zijn invallen voor gedaan en hebben mensen boetes gekregen. Schijt aan Corona party's mogen dus gewoon.

Ook samenkomsten buiten de publieke ruimte vallen onder het eerste lid. Zo kan worden
opgetreden tegen bijvoorbeeld ‘coronafeestjes’ in studentenhuizen, garages, loodsen en
dergelijke

Maar je mag niets meer samen....

Vreemd, hier zijn invallen voor gedaan en hebben mensen boetes gekregen.

Wat is eigenlijk de exacte en juiste vertrektijd van een trein?
Bij een vertrektijd volgens de dienstregeling van 14:25uur is dat dan
14:25:00 ?
14:25:30 ??
14:25:59 ???

Op mijn opmerking dat men dan dus op overstapstations beter de vertrektijd een minuut kan vervroegen, immers kan je dan toch al niet meer naar binnen, werd niet echt enthousiast gereageerd.

Hoe is dit precies anders dan eurobonds?

RIVM start met Infectieradar

Het RIVM Rijksinstituut voor Volksgezondheid en Milieu houdt op verschillende manieren de verspreiding van infectieziekten in de gaten. Dat geldt ook voor het nieuwe coronavirus. Een van die manieren is door te kijken naar mensen met klachten die kunnen wijzen op een infectie. Dat doen we met Infectieradar. Een onderzoek waar iedereen in Nederland aan mee kan doen.

Deelnemers geven één keer per week door of zij in de afgelopen week koorts of andere klachten hadden. Ook als mensen geen klachten hebben, geven ze dit door. Zo kunnen we signalen van toename of afname van infecties, waaronder besmettingen met COVID-19 eerder oppikken. Infectieradar is sinds 17 maart actief met 22.000 deelnemers. Het RIVM streeft naar in ieder geval 100.000 deelnemers. Op dit moment kunnen er maximaal 150.000 mensen mee doen. Als er meer mensen mee willen doen, dan wordt dit uitgebreid.

Waarom Infectieradar?
We weten dat veel mensen met een besmetting met het nieuwe coronavirus milde of weinig klachten hebben en niet naar de huisarts gaan. Ook wordt niet iedereen getest. Zo is het lastig te volgen hoe het nieuwe coronavirus zich ontwikkelt in Nederland. Met hulp van mensen uit het hele land kan dat beter en kunnen we samen de vinger aan de pols houden. Juist nu er maatregelen versoepeld zijn is het belangrijk om ook naar klachten te kijken die niet bij de huisarts worden gemeld.

Hoe werkt de Infectieradar?
Mensen die zich als deelnemer aan Infectieradar hebben aangemeld geven één keer per week door aan Infectieradar of zij in de afgelopen week koorts of andere klachten hadden. Hiermee kan het RIVM volgen hoe gezondheidsklachten verspreid zijn in Nederland en hoe zich dat ontwikkelt in de tijd. Die gegevens kan het RIVM gebruiken voor wetenschappelijk onderzoek naar de verspreiding van het nieuwe coronavirus. In de toekomst kan het RIVM dat ook voor andere virussen en infectieziekten gebruiken.

Deelnemers ontvangen eerst een registratie met vragen over hun achtergrond. Over hun werk, leeftijd, en bestaande ziekten en aandoeningen. Daarna krijgen zij elke week een e-mail met de vraag of en zo ja, welke klachten zij in de afgelopen week hadden. Het gaat dan om klachten als een loopneus, hoesten, niezen en koorts. Ook als iemand geen klachten heeft is dit belangrijk om in te vullen. Als de deelnemer geen klachten heeft duurt het invullen ongeveer 30 seconden. Bij klachten kost invullen van de vragenlijst ongeveer 3 tot 5 minuten tijd.

Toestemmingsverklaring verwerken van persoonsgegevens

Hoe is dit precies anders dan eurobonds?

Geen 1,5 meter afstand

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera

mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera
mRNA-1273 was generally safe and well tolerated
mRNA-1273 provided full protection against viral replication in the lungs in a mouse challenge model
Anticipated dose for Phase 3 study between 25 µg and 100 µg; expected to start in July

a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg dose levels. All participants ages 18-55 (n=15 per cohort) across all three dose levels seroconverted by day 15 after a single dose. At day 43, two weeks following the second dose, at the 25 µg dose level (n=15), levels of binding antibodies were at the levels seen in convalescent sera (blood samples from people who have recovered from COVID-19) tested in the same assay. At day 43, at the 100 µg dose level (n=10), levels of binding antibodies significantly exceeded the levels seen in convalescent sera. Samples are not yet available for remaining participants.

At this time, neutralizing antibody data are available only for the first four participants in each of the 25 µg and 100 µg dose level cohorts. Consistent with the binding antibody data, mRNA-1273 vaccination elicited neutralizing antibodies in all eight of these participants, as measured by plaque reduction neutralization (PRNT) assays against live SARS-CoV-2. The levels of neutralizing antibodies at day 43 were at or above levels generally seen in convalescent sera.

mRNA-1273 was generally safe and well tolerated, with a safety profile consistent with that seen in prior Moderna infectious disease vaccine clinical studies. The sole incidence of a grade 3 adverse event in the 25 µg and 100 µg dose cohorts was a single participant at 100 µg who experienced grade 3 erythema (redness) around the injection site. To date, the most notable adverse events were seen at the 250 µg dose level, comprising three participants with grade 3 systemic symptoms, only following the second dose. All adverse events have been transient and self-resolving. No grade 4 adverse events or serious adverse events have been reported.

Preclinical results from a viral challenge study in mice conducted in collaboration with NIAID and its academic partners are also available. In this study, vaccination with mRNA-1273 prevented viral replication in the lungs of animals challenged with SARS-CoV-2. Neutralizing titers in Phase 1 clinical trial participants at the 25 µg and 100 µg dose levels were consistent with neutralizing titers that were protective in the mouse challenge model.

Based on the interim Phase 1 data, the Moderna-led Phase 2 study will be amended to study two dose levels, 50 µg and 100 µg, with the aim of selecting a dose for pivotal studies. The NIAID-led Phase 1 study is being amended to include a 50 µg dose level cohort across each of the three age groups. Moderna anticipates the dose for the Phase 3 study to be between 25 µg and 100 µg and expects Phase 3 trial initiation in July, subject to finalization of the clinical trial protocol.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”

“With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” said Stéphane Bancel, Chief Executive Officer at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”

Funding from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), supported the planning for the Phase 2 and Phase 3 studies of mRNA-1273 and will also support the execution of these studies, as well as the scale-up of mRNA-1273 manufacturing both at the Company’s facilities and that of its strategic collaborator, Lonza Ltd.

About mRNA-1273

mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing.

On May 6, the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application for mRNA-1273 allowing it to proceed to a Phase 2 study, which is expected to begin shortly. On May 12, the FDA granted mRNA-1273 Fast Track designation. Moderna is finalizing the protocol for a Phase 3 study, expected to begin in July 2020. A summary of the company’s work to date on SARS-CoV-2 can be found here.

About Moderna’s Prophylactic Vaccines Modality

Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,400 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.

The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated manufacturing plant which enables the promise of the technology platform.

Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

Vaccines against respiratory infections

Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)
RSV vaccine for young children (mRNA-1345)
Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653)
Novel coronavirus (SARS-CoV-2) vaccine (mRNA-1273)
Influenza H7N9 (mRNA-1851)
Vaccines against infections transmitted from mother to baby

Cytomegalovirus (CMV) vaccine (mRNA-1647)
Zika vaccine (mRNA-1893 with BARDA)
Vaccines against highly prevalent viral infections

Epstein-Barr virus (EBV) vaccine (mRNA-1189)

To date, Moderna has demonstrated positive Phase 1 data readouts for seven prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3, CMV and Zika). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past five years. To learn more, visit http://www.modernatx.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine against the novel coronavirus, the parameters and timing of the Phase 1 and planned Phase 2 and 3 studies of mRNA-1273, the Company’s investment in manufacturing, and the Company’s intentions regarding vaccine dose production. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at http://www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Kunnen wel een succesje gebruiken lijkt me of wat zijn ze normaal gesproken in vredesnaam aan het doen.

Could genetics play a role in the severity of COVID-19?

April 8, 2020 By 23andMe under 23andMe Research

Scientists around the world are racing to understand COVID-19 and the novel coronavirus that causes the disease. Among the questions they’re asking: Why do most people who are infected show mild to moderate symptoms (or possibly no symptoms at all), whereas others develop severe disease?

We know that certain factors — like advanced age or underlying health conditions like heart disease and diabetes — can make someone more likely to develop severe symptoms, including pneumonia. But even young, healthy people can develop severe symptoms and die from COVID-19. Why might that be?

Could genetics play a role?

With the help of our research participants, 23andMe is launching a research study to try to answer that question. Before we describe 23andMe’s planned research, here’s some of what is known about the role of genetics in other infectious diseases.

Human genetics plays a role in many infectious diseases
We know from past research that genetics can influence a person’s susceptibility to different infectious diseases — including whether they’re infected and how severe their disease becomes.

For example:

Particular genetic variants in a gene called HBB can make people less susceptible to infection by the parasite that causes malaria. HBB contains instructions for making the hemoglobin protein that carries oxygen inside our red blood cells.
A particular genetic variant in a gene called CCR5 can protect people from HIV infection by preventing the virus from being able to enter certain T cells in our immune system. CCR5 codes for a protein that sits on the surface of those T cells.
People with a particular variant in the FUT2 gene are much less likely to be infected by norovirus. FUT2 codes for an enzyme that helps determine whether certain molecules are present on the surface of our gut cells.
In addition, genetic variants in HLA genes may explain the differences in response to several different conditions. This group of genes helps the immune system distinguish the body’s own proteins from proteins made by foreign invaders like viruses and bacteria. Studies have found that variants in these genes may help explain why HIV progresses more quickly in some people than others. Variants in the HLA genes may also influence why some people can clear hepatitis B infection and others don’t, instead ending up with a chronic disease. And variants in this same group of genes could offer insight into why some (but not all) people infected with dengue virus experience severe complications. In 2017, scientists at 23andMe published a genetic study that identified almost 60 genetic variants associated with susceptibility to one of 17 different infectious diseases, and many of those variants were in HLA genes.

What about COVID-19?
So, could genetics help explain why certain people develop severe COVID-19 and others develop only mild or undetectable symptoms?

It’s too early to say for sure, but some scientists think that’s likely the case. At least a couple of studies have started looking for clues.

For example, in order to get inside our cells, the virus that causes COVID-19 latches onto a human protein called ACE2. And scientists identified genetic variants in and near the ACE2 gene that could impact how much ACE2 protein is made, or how the protein functions. This could make it easier or tougher for the virus to slip inside a person’s cells and make them sick. In another study, scientists reported that a person’s blood type — which is determined by the ABO gene — might influence their likelihood of being infected by the virus. While these preliminary observations are intriguing, more research in different populations and in larger groups of patients is needed to validate these and other findings.

How 23andMe Research could make a difference
23andMe’s unique research model, with millions of customers consented to participate, offers our scientists a powerful tool for potential insight into the role genetics may play in explaining differences in the severity of the novel coronavirus.

One way to identify genetic variants that contribute to disease severity is a genome-wide association study or GWAS. In a GWAS, scientists compare the DNA of people who had severe symptoms to the DNA of people who had milder symptoms, or even no symptoms at all. Genetic variants that are more common in one of these groups of participants than the other represent genetic associations with COVID-19 severity.

And that’s just one question that 23andMe Research hopes to answer. We’ll compare genetic variants in people who get very sick with variants in people who had milder symptoms or haven’t gotten sick. By identifying genetic variants that are more common in people who experienced severe disease, scientists may be able to better understand who’s most at risk. Perhaps even more importantly, these genetic studies can also help us gain new insights into how the novel coronavirus infects our cells and impacts our bodies. And those insights might give us clues to potential targets for new drugs or vaccines.

Learn more about 23andMe’s study here.

April 8, 2020 By 23andMe under 23andMe Research

Het meest bizarre van dit alles is nog om straks weer regio's in een lockdown te gooien ook als het totaal niet nodig is. Iemand anders betaalt er toch wel voor.

Hele slechte ontwikkeling.

gisteren om 23:56
VS bereikt twee macabere mijlpalen
De Verenigde Staten heeft twee mijlpalen gehaald die het liever vermeden had. Volgens cijfers van de Johns Hopkins University zijn er nu meer dan 1,5 miljoen Amerikanen besmet geraakt met het coronavirus.

Tevens steeg het dodental als gevolg van het virus tot boven de 90.000. Daarmee is de Verenigde Staten volgens de officiële cijfers met grote afstand het hardst getroffen land ter wereld.

Mijn kabeltje komt al via airmail.

Creatief boekhouden,